我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

尿酸对大鼠血管平滑肌细胞增殖的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第3期
页码:
218-220,224
栏目:
基础研究
出版日期:
2005-05-05

文章信息/Info

Title:
Effect of uric acid on proliferation of rat vascular smooth muscle cells
作者:
孙海鸥1姬秋和1马 恒2胡玉珍2高峰2
第四军医大学:1.西京医院内分泌科,2.生理学教研室,陕西 西安 710032
Author(s):
SUN Haiou1 JI Qiuhe1 MA Heng2 HU Yuzhen2 GAO Feng2
1.Department of Endocrinology, Xijing Hospital, 2.Department of Physiology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
关键词:
尿酸平滑血管细胞学细胞周期
Keywords:
uric acid musclesmoothvascular cytology cell cycle
分类号:
R543
DOI:
-
文献标识码:
A
摘要:
目的 观察尿酸(uric acid,UA)对动脉粥样硬化关键环节——血管平滑肌细胞增殖的影响。 方法 以体外培养的大鼠血管平滑肌细胞为实验对象,分为对照组、尿酸组和洛沙坦+尿酸组,每组处理后用MTT法分析细胞增殖活力,流式细胞仪(flow cytometry,FCM)检测细胞增殖周期。 结果 尿酸作用后培养细胞的MTT值明显高于对照组(40 mg/L UA:0.65±0.06 ;对照:0.37±0.07, P<0.01),并且存在剂量依赖效应;尿酸所致上述效应还存在时间依赖性;洛沙坦能部分阻断尿酸刺激血管平滑肌细胞增殖作用。流式细胞分析显示尿酸作用使血管平滑肌细胞G1期细胞比例减少,S期细胞比例增加。结论 尿酸能够促进血管平滑肌细胞增殖,存在剂量及时间依赖效应;该作用可能部分通过血管紧张素Ⅱ的受体介导。探讨氯沙坦对心脏保护作用与肝细胞生长因子(HGF)的关系。方法 实验动物为自发性高血压大鼠(SHR)36只,分别为6周龄,14周龄和24周龄。分为两组,一组为氯沙坦组(SL),另一组为对照组(SC);以Wistar大鼠为正常对照组(WC),年龄和体质量配比,每组各6只,雌雄配对。SL组每天按30 mg/kg灌胃法喂服,对照组采用灌胃法喂服等量蒸馏水,疗程6周。实验结束后分别测量血压,左室质量,采用M30apoptosense ELISA法测心肌细胞凋亡数量及血浆,组织HGF浓度,心肌胶原容积和血管周围胶原容积。结果 治疗6周后,与未服药的对照组相比,SL组不但血压下降,同时左室质量指数降低,间质纤维化及血管周围纤维化程度减轻,心肌细胞凋亡数量减少,血浆HGF降低,伴有组织HGF浓度升高。结论 氯沙坦能够促进组织HGF分泌,恢复其自身修复能力而逆转心室重构。同时改善内皮功能,维护心肌组织与内皮的稳定性,可能有降低心脑血管病危险性的作用。
Abstract:
AIM To observe the effect of uric acid on the proliferation of rat vascular smooth muscle cells, the key step of atherosclerosis. METHODS Cultured vascular smooth muscle cells(VSMC) were used and divided into control group, Uric acid(UA) group(20 mg/L, 40 mg/L, 60 mg/L )and UA+losartan group. The UA (40 mg/L) group was further divided into three subgroups on the basis of different incubation times (24, 48, 72 hours) . MTT assay and flow cytometry (FCM) were used to detect the proliferation of the cells. RESULTS UA significently increased the values of MTT absorbance(40 mg/L UA:0.65±0.06, P<0.01 compared with control) in a time and dosedependent manner. This effect co uld be partly blocked by losartan (0.59±0.05,P<0.01 compared with control). FCM showed that the percentage of G1 phase cells decreased and the percentage of S phase cells increased after UA treatment. CONCLUSION UA can accelerate the proliferation of VSMC in a time and dosedependent manner, and the receptor of angiotensin Ⅱmay play a role in the effects of UA stimulated VSMC proliferation.

参考文献/References

[1] Alderman MH. Uric acid and cardiovascular risk[J]. Curr Opin Pharmacol, 2002, 2(2):126-130.

[2] 司徒镇强, 吴军正. 细胞培养[M]. 西安:世界图书出版公司,996.69-71.

[3] Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism[J]. Am J Physiol Renal Physiol, 2002, 282(6):F991-F997.

[4] Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of saltsensitivity[J]. Hypertension, 2002, 40(3):355-360.

[5] Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease[J]. J Am Soc Nephrol, 2002, 13(12):28882897.

[6] Yamaguchi T, Ida T, Hiraga M, et al. Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy3methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation[J]. Yakugaku Zasshi, 2004, 124(3):159-163.

[7] Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum uric acid concentrations in humans[J]. Jpn Heart J, 2003, 44(4):527-536.

[8] Nagahama K, Iseki K, Inoue T, et al. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan[J]. Hypertens Res, 2004, 27(4):227-233.

[9] 王莉, 赵霞, 张南雁,等. T2DM颈动脉粥样硬化与血尿酸关系[J]. 心脏杂志, 2004,16(2):132-134.

[10] Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan[J]. Curr Med Res Opin, 2004, 20(3):369-379.

备注/Memo

备注/Memo:
收稿日期:2004-07-13.基金资助:陕西省卫生厅资金资助(04D25)
更新日期/Last Update: 2010-01-05